We develop GPCR modulators for Idiopathic Pulmonary Fibrosis (IPF) and other inflammatory and metabolic conditions
About Innospera Pharma
Innospera is a privately-owned biotech company near clinical stage, developing small molecule modulators of 7-transmembrane receptors involved in a broad range
of chronic and fibrotic conditions.The company’s lead drug candidates target key G-protein coupled receptors (GPCR) involved in fibroaging and inflammaging, including idiopathic pulmonary
fibrosis (IPF), a condition with direshort-term prognosis. Innospera also develops multiple other modulators with promising potency in other medical conditions with pressing unmet needs.
Leadership team
Board of Directors
Pierre Laurin, BPharm, MSc
Executive Chairman and co-founder, Innospera
François Ravenelle, PhD
President and CEO, Innospera
Lyne Gagnon, PhD
CSO and co-founder, Innospera
Patricia Escoffier, PhD
Principal, Seido Capital
​
Hélène Moore, MBA
Director, Anges Québec
​
Denis Garceau, BPharm, PhD
Ex-CSO, Bellus Health
​
Hubert Sibre, LLB
Partner, Miller Thomson
​
Maxime Daigle, CPA
Board Observer, Director, Investissement Québec
Our Science
Our scientists leverage decades of experience in developing small molecule GPCR modulators to address inflammatory-driven conditions that meet three criteria:
1
Target receptors drive the severity of the selected medical condition, the disease progression or low survival rates
2
Medical condition remains an unmet medical need and has a clear regulatory pathway
3
Our lead drug candidates demonstrate superiority over:
- standard of care
- competitors’ late-stage clinical assets
Fibrosis Reduction & Metabolic Regulation: A Balancing Act
Balance between GPR84 and GPR40 plays a significant role in the modulation of the fibrotic and metabolic processes.
Our library of small molecule modulators allows us to re-establish a more favourable GPR84 / GPR40 balance.
Our Lead Product: ING-006
Idiopathic Pulmonary Fibrosis (IPF) affects approximately 140,000 adults in the USA alone, nearly 3 million worldwide.
While the exact cause of IPF remains unknown, repeated injuries to lung cells induce abnormal wound healing processes and life-threatening lung scarring.
IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only 3 to 5 years after diagnosis.
Our Pipeline
